Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Prat

Showing results (241-250 of 268) with videos related to

Pageof 27
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Arxiv|July 30, 2025
Monitoring morphometric drift in lifelong learning segmentation of the spinal cordEnamundram Naga Karthik, Sandrine Bédard, Jan Valošek, et al.
Imaging Neuroscience (Cambridge, Mass.)|January 26, 2026
Monitoring morphometric drift in lifelong learning segmentation of the spinal cordEnamundram Naga Karthik, Sandrine Bédard, Jan Valošek, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2026
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centersPierre-Louis Benveniste, Laurent Létourneau-Guillon, David Araujo, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Pageof 27

Showing results (241-250 of 268) with videos related to

Sort By:
Pageof 27
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Arxiv|July 30, 2025
Monitoring morphometric drift in lifelong learning segmentation of the spinal cordEnamundram Naga Karthik, Sandrine Bédard, Jan Valošek, et al.
Imaging Neuroscience (Cambridge, Mass.)|January 26, 2026
Monitoring morphometric drift in lifelong learning segmentation of the spinal cordEnamundram Naga Karthik, Sandrine Bédard, Jan Valošek, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2026
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centersPierre-Louis Benveniste, Laurent Létourneau-Guillon, David Araujo, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
Pageof 27